Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3300054 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| LY3300054 | EXPERIMENTAL | LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle. |
| LY3300054 + Ramucirumab | EXPERIMENTAL | LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle. |
| Abemaciclib + LY3300054 | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + Abemaciclib (Concurrent Dosing) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + Abemaciclib | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required. |
| LY3300054 + Merestinib | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle. |
| LY3300054 Expansion (Metastatic Cutaneous Melanoma) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 Expansion (MSI-H Solid Tumors) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 of a 28 day cycle. |
| : LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H) | EXPERIMENTAL | LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 + LY3321367 Expansion | EXPERIMENTAL | LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 + Merestinib (Pancreatic Cancer) Expansion | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle. |
| Name | Type | Description |
|---|---|---|
| LY3300054 | DRUG | Administered IV |
| Ramucirumab | DRUG | Administered IV |
| Abemaciclib | DRUG | Administered orally |
| Merestinib | DRUG | Administered orally |
| LY3321367 | DRUG | Administered IV |
Inclusion Criteria: * Histologic or cytologic confirmation of advanced solid tumor. * For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin. * For LY3...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY3300054 is an investigational anti-PD-L1 checkpoint antibody being developed by Eli Lilly and Company for advanced refractory solid tumors. It was studied both as a single agent and in combination with other therapies in a Phase 1 clinical trial. It is not yet approved and remains in clinical development.
LY3300054 was studied in adults with advanced refractory solid tumors, including microsatellite instability-high (MSI-H) solid tumors, cutaneous melanoma, pancreatic cancer, and HR+HER2- breast cancer. The trial enrolled participants whose tumors had progressed despite prior treatment. It is investigational and has not been approved for any indication.
LY3300054 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study evaluating the agent alone and in combination in participants with advanced refractory solid tumors.
LY3300054 is in Phase 1 development. Its single registered trial, NCT02791334, was a Phase 1 study that has been completed, with 164 participants enrolled. The drug is investigational and has not received FDA approval for any indication.
LY3300054 was evaluated in one Phase 1 trial, NCT02791334, titled a study of anti-PD-L1 checkpoint antibody LY3300054 alone and in combination in participants with advanced refractory solid tumors. The trial enrolled 164 participants across the United States, Belgium, Canada, France, South Korea, Spain, and Taiwan, and it is now completed.
LY3300054 is an anti-PD-L1 checkpoint antibody. It targets the PD-L1 immune checkpoint protein, which tumor cells use to suppress T-cell activity. By binding PD-L1, the antibody is designed to block this inhibitory signal and restore the immune system's ability to recognize and attack tumor cells.